Novo Nordisk A/S unveiled details from a closely watched study that supports the use of Wegovy, its blockbuster weight-loss drug, to cut heart attacks and deaths in obesity patients with a history of cardiovascular disease.

The results are “game-changing,” Eugene Yang, the chair of the American College of Cardiology’s prevention section, said in an interview. Doctors at the American Heart Association’s annual conference in Philadelphia erupted into several rounds of applause when the data were presented.

ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9c3%2BMamhmaWFkxKazzq%2BwZq%2BVnrSpwIylpqyrXZm%2FtrOMppiyZZGhwLB506ucmqxdnbKivtNmm6KrlZbApnnSraydsV2otbDD0g%3D%3D